688656 浩欧博
已收盘 02-13 15:00:00
资讯
新帖
简况
12月30日浩欧博跌7.66%，农银医疗保健股票基金重仓该股
证券之星 · 2025-12-30
12月30日浩欧博跌7.66%，农银医疗保健股票基金重仓该股
12月18日浩欧博跌7.25%，农银医疗保健股票基金重仓该股
证券之星 · 2025-12-18
12月18日浩欧博跌7.25%，农银医疗保健股票基金重仓该股
12月16日浩欧博跌5.52%，农银医疗保健股票基金重仓该股
证券之星 · 2025-12-16
12月16日浩欧博跌5.52%，农银医疗保健股票基金重仓该股
浩欧博(688656.SH)：免疫球蛋白G4(IgG4)测定试剂盒(磁微粒化学发光法)获得医疗器械注册证
智通财经 · 2025-12-08
浩欧博(688656.SH)：免疫球蛋白G4(IgG4)测定试剂盒(磁微粒化学发光法)获得医疗器械注册证
12月1日浩欧博涨5.80%，农银医疗保健股票基金重仓该股
证券之星 · 2025-12-01
12月1日浩欧博涨5.80%，农银医疗保健股票基金重仓该股
11月26日浩欧博涨9.38%，农银医疗保健股票基金重仓该股
证券之星 · 2025-11-26
11月26日浩欧博涨9.38%，农银医疗保健股票基金重仓该股
每周股票复盘：浩欧博（688656）股东大会通过取消监事会议案
证券之星 · 2025-11-16
每周股票复盘：浩欧博（688656）股东大会通过取消监事会议案
浩欧博（688656）披露取消监事会及修订公司章程事项，11月14日股价下跌0.22%
证券之星 · 2025-11-14
浩欧博（688656）披露取消监事会及修订公司章程事项，11月14日股价下跌0.22%
浩欧博（688656）披露双润正安要约收购2025年第三季度持续督导意见，11月12日股价上涨0.35%
证券之星 · 2025-11-12
浩欧博（688656）披露双润正安要约收购2025年第三季度持续督导意见，11月12日股价上涨0.35%
每周股票复盘：浩欧博（688656）拟取消监事会并召开Q3业绩说明会
证券之星 · 2025-11-09
每周股票复盘：浩欧博（688656）拟取消监事会并召开Q3业绩说明会
浩欧博（688656）披露拟取消监事会并由审计委员会行使监事会职权，11月06日股价上涨0.34%
证券之星 · 2025-11-06
浩欧博（688656）披露拟取消监事会并由审计委员会行使监事会职权，11月06日股价上涨0.34%
11月5日浩欧博涨12.63%，农银医疗保健股票基金重仓该股
证券之星 · 2025-11-05
11月5日浩欧博涨12.63%，农银医疗保健股票基金重仓该股
每周股票复盘：浩欧博（688656）股东户数增19.69%，Q3净利增113%
证券之星 · 2025-11-02
每周股票复盘：浩欧博（688656）股东户数增19.69%，Q3净利增113%
浩欧博（688656）2025年三季报简析：净利润同比下降1.41%，公司应收账款体量较大
证券之星 · 2025-10-31
浩欧博（688656）2025年三季报简析：净利润同比下降1.41%，公司应收账款体量较大
图解浩欧博三季报：第三季度单季净利润同比增长113.01%
证券之星 · 2025-10-29
图解浩欧博三季报：第三季度单季净利润同比增长113.01%
每周股票复盘：浩欧博（688656）与罗氏诊断签合作框架协议
证券之星 · 2025-10-26
每周股票复盘：浩欧博（688656）与罗氏诊断签合作框架协议
浩欧博（688656）披露签订合作框架协议暨风险提示公告，10月21日股价下跌1.41%
证券之星 · 2025-10-21
浩欧博（688656）披露签订合作框架协议暨风险提示公告，10月21日股价下跌1.41%
浩欧博(688656.SH)与罗氏诊断就化学发光自身抗体检测产品领域开展合作
智通财经 · 2025-10-21
浩欧博(688656.SH)与罗氏诊断就化学发光自身抗体检测产品领域开展合作
10月10日浩欧博跌6.17%，农银医疗保健股票基金重仓该股
证券之星 · 2025-10-10
10月10日浩欧博跌6.17%，农银医疗保健股票基金重仓该股
浩欧博(688656.SH)：MM09舌下喷雾剂III期临床试验完成首批受试者入组
智通财经 · 2025-09-24
浩欧博(688656.SH)：MM09舌下喷雾剂III期临床试验完成首批受试者入组
暂无数据
公司概况
公司名称：
江苏浩欧博生物医药股份有限公司
所属行业：
医药制造业
上市日期：
2021-01-13
主营业务：
江苏浩欧博生物医药股份有限公司的主营业务是体外诊断试剂的研发、生产和销售。公司的主要产品是IgE检测、食物特异性IgG检测、自免产品。
发行价格：
35.26
{"stockData":{"symbol":"688656","market":"SH","secType":"STK","nameCN":"浩欧博","latestPrice":147.61,"timestamp":1770966000000,"preClose":143.92,"halted":0,"volume":922709,"delay":0,"changeRate":0.0256,"floatShares":63479700,"shares":63479700,"eps":0.5739,"marketStatus":"已收盘","change":3.69,"latestTime":"02-13 15:00:00","open":143.91,"high":150.6,"low":141.9,"amount":136000000,"amplitude":0.0605,"askPrice":147.61,"askSize":2,"bidPrice":147.3,"bidSize":2,"shortable":0,"etf":0,"ttmEps":0.5739,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771896600000},"marketStatusCode":5,"adr":0,"adjPreClose":143.92,"symbolType":"stock_kcb","openAndCloseTimeList":[[1770946200000,1770953400000],[1770958800000,1770966000000]],"highLimit":158.31,"lowLimit":129.53,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":63479740,"isCdr":false,"pbRate":11.3,"roa":"--","peRate":257.205088,"roe":"3.19%","epsLYR":0.59,"committee":0.266667,"marketValue":9370000000,"turnoverRate":0.0145,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-02-24。","afterMarket":{"amount":0,"volume":0,"close":147.61,"buyVolume":0,"sellVolume":0,"time":1770968037558,"indexStatus":"已收盘 02-13 15:30:00","preClose":143.92},"floatMarketCap":9370000000},"requestUrl":"/m/hq/s/688656/tweets","defaultTab":"tweets","newsList":[{"id":"2595276290","title":"12月30日浩欧博跌7.66%，农银医疗保健股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2595276290","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595276290?lang=zh_cn&edition=full","pubTime":"2025-12-30 15:34","pubTimestamp":1767080095,"startTime":"0","endTime":"0","summary":"证券之星消息，12月30日浩欧博跌7.66%，收盘报167.23元，换手率2.27%，成交量1.44万手，成交额2.5亿元。该股为医疗器械、体外诊断概念热股。重仓浩欧博的公募基金请见下表：该股最近90天内共有1家机构给出评级，增持评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为农银汇理基金的农银医疗保健股票。该公募基金现任基金经理为梦圆。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000020267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688656","BK0239"],"gpt_icon":0},{"id":"2592978126","title":"12月18日浩欧博跌7.25%，农银医疗保健股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2592978126","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592978126?lang=zh_cn&edition=full","pubTime":"2025-12-18 15:34","pubTimestamp":1766043244,"startTime":"0","endTime":"0","summary":"证券之星消息，12月18日浩欧博跌7.25%，收盘报182.25元，换手率2.28%，成交量1.44万手，成交额2.68亿元。重仓浩欧博的公募基金请见下表：该股最近90天内共有1家机构给出评级，增持评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为农银汇理基金的农银医疗保健股票。该公募基金现任基金经理为梦圆。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800017850.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688656","BK0239"],"gpt_icon":0},{"id":"2591404609","title":"12月16日浩欧博跌5.52%，农银医疗保健股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2591404609","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591404609?lang=zh_cn&edition=full","pubTime":"2025-12-16 15:36","pubTimestamp":1765870602,"startTime":"0","endTime":"0","summary":"证券之星消息，12月16日浩欧博跌5.52%，收盘报196.69元，换手率1.31%，成交量8311.0手，成交额1.65亿元。该股为医疗器械、体外诊断概念热股。重仓浩欧博的公募基金请见下表：该股最近90天内共有1家机构给出评级，增持评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为农银汇理基金的农银医疗保健股票。该公募基金现任基金经理为梦圆。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600020151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688656","BK0239"],"gpt_icon":0},{"id":"2589838098","title":"浩欧博(688656.SH)：免疫球蛋白G4(IgG4)测定试剂盒(磁微粒化学发光法)获得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2589838098","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589838098?lang=zh_cn&edition=full","pubTime":"2025-12-08 15:47","pubTimestamp":1765180039,"startTime":"0","endTime":"0","summary":"智通财经APP讯，浩欧博(688656.SH)发布公告，公司全资子公司湖南浩欧博生物医药有限公司于近日获得1项由湖南省药品监督管理局核准签发的医疗器械注册证，涉及产品：“免疫球蛋白G4(IgG4)测定试剂盒(磁微粒化学发光法)”。上述医疗器械注册证的取得，进一步丰富了公司化学发光平台检测菜单，有助于提升公司市场综合竞争力，对公司及子公司的可持续性发展将产生积极影响和促进作用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688656","BK1574","BK0239","BK1222","09997","BK1100","BK1583","09996","159883"],"gpt_icon":0},{"id":"2588740744","title":"12月1日浩欧博涨5.80%，农银医疗保健股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2588740744","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588740744?lang=zh_cn&edition=full","pubTime":"2025-12-01 15:33","pubTimestamp":1764574418,"startTime":"0","endTime":"0","summary":"证券之星消息，12月1日浩欧博涨5.80%创60日新高，收盘报211.5元，换手率2.09%，成交量1.33万手，成交额2.78亿元。该股为医疗器械、体外诊断概念热股。重仓浩欧博的公募基金请见下表：该股最近90天内共有1家机构给出评级，增持评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为农银汇理基金的农银医疗保健股票。该公募基金现任基金经理为梦圆。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100012760.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688656","BK0239"],"gpt_icon":0},{"id":"2586239673","title":"11月26日浩欧博涨9.38%，农银医疗保健股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2586239673","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586239673?lang=zh_cn&edition=full","pubTime":"2025-11-26 15:34","pubTimestamp":1764142455,"startTime":"0","endTime":"0","summary":"证券之星消息，11月26日浩欧博涨9.38%创60日新高，收盘报201.8元，换手率2.71%，成交量1.72万手，成交额3.44亿元。重仓浩欧博的公募基金请见下表：该股最近90天内共有1家机构给出评级，增持评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为农银汇理基金的农银医疗保健股票。该公募基金现任基金经理为梦圆。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600017642.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688656"],"gpt_icon":0},{"id":"2583651405","title":"每周股票复盘：浩欧博（688656）股东大会通过取消监事会议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2583651405","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583651405?lang=zh_cn&edition=full","pubTime":"2025-11-16 03:53","pubTimestamp":1763236390,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，浩欧博报收于182.47元，较上周的185.0元下跌1.37%。本周关注点公司公告汇总：浩欧博2025年第四次临时股东大会审议通过取消监事会及修订公司章程的议案。江苏浩欧博生物医药股份有限公司2025年第四次临时股东大会决议公告江苏浩欧博生物医药股份有限公司于2025年11月14日召开2025年第四次临时股东大会，审议通过了关于取消监事会、修订《公司章程》并办理工商变更登记的议案，以及关于修订及制定公司部分治理制度的议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688656"],"gpt_icon":0},{"id":"2583350217","title":"浩欧博（688656）披露取消监事会及修订公司章程事项，11月14日股价下跌0.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583350217","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583350217?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:41","pubTimestamp":1763131281,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，浩欧博报收于182.47元，较前一交易日下跌0.22%，最新总市值为115.83亿元。该股当日开盘182.88元，最高182.88元，最低178.01元，成交额达8901.8万元，换手率为0.78%。近日，江苏浩欧博生物医药股份有限公司发布2025年第四次临时股东大会决议公告。公告显示，公司于2025年11月14日召开2025年第四次临时股东大会，审议通过了关于取消监事会、修订《公司章程》并办理工商变更登记的议案，以及关于修订及制定公司部分治理制度的议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400042039.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688656","BK0239"],"gpt_icon":0},{"id":"2582377581","title":"浩欧博（688656）披露双润正安要约收购2025年第三季度持续督导意见，11月12日股价上涨0.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582377581","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582377581?lang=zh_cn&edition=full","pubTime":"2025-11-12 22:19","pubTimestamp":1762957157,"startTime":"0","endTime":"0","summary":"截至2025年11月12日收盘，浩欧博报收于180.25元，较前一交易日上涨0.35%，最新总市值为114.42亿元。该股当日开盘179.13元，最高183.44元，最低177.39元，成交额达1.2亿元，换手率为1.05%。公司近日发布公告，中国国际金融股份有限公司发布了关于双润正安信息咨询（北京）有限公司要约收购江苏浩欧博生物医药股份有限公司之2025年第三季度持续督导意见。公告显示，中金公司作为财务顾问指出，本次要约收购已于2025年2月14日完成股份过户。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200041269.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688656","BK0239"],"gpt_icon":0},{"id":"2582861657","title":"每周股票复盘：浩欧博（688656）拟取消监事会并召开Q3业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2582861657","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582861657?lang=zh_cn&edition=full","pubTime":"2025-11-09 03:53","pubTimestamp":1762631592,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，浩欧博报收于185.0元，较上周的164.35元上涨12.56%。本周关注点公司公告汇总：浩欧博拟取消监事会，由董事会审计委员会行使监事会职权。公司公告汇总：浩欧博将于2025年11月17日召开第三季度业绩说明会。公司公告汇总江苏浩欧博生物医药股份有限公司拟取消监事会，由董事会下设的审计委员会行使监事会职权，相应废止《监事会议事规则》，并对《公司章程》中涉及监事会、监事的相关条款进行修订，同时办理工商变更登记。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688656"],"gpt_icon":0},{"id":"2581091165","title":"浩欧博（688656）披露拟取消监事会并由审计委员会行使监事会职权，11月06日股价上涨0.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581091165","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581091165?lang=zh_cn&edition=full","pubTime":"2025-11-06 22:18","pubTimestamp":1762438703,"startTime":"0","endTime":"0","summary":"截至2025年11月6日收盘，浩欧博报收于191.0元，较前一交易日上涨0.34%，最新总市值为121.25亿元。该股当日开盘188.0元，最高197.0元，最低184.17元，成交额达2.27亿元，换手率为1.86%。根据近日发布的《江苏浩欧博生物医药股份有限公司2025年第四次临时股东大会会议资料》，公司拟取消监事会，由董事会下设的审计委员会行使监事会职权，相应废止《监事会议事规则》，并对《公司章程》中涉及监事会、监事的相关条款进行修订，同时办理工商变更登记。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600038158.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688656"],"gpt_icon":0},{"id":"2581674929","title":"11月5日浩欧博涨12.63%，农银医疗保健股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2581674929","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581674929?lang=zh_cn&edition=full","pubTime":"2025-11-05 16:29","pubTimestamp":1762331352,"startTime":"0","endTime":"0","summary":"证券之星消息，11月5日浩欧博涨12.63%创60日新高，收盘报190.35元，换手率3.29%，成交量2.09万手，成交额3.81亿元。重仓浩欧博的公募基金请见下表：该股最近90天内共有2家机构给出评级，增持评级2家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为农银汇理基金的农银医疗保健股票。该公募基金现任基金经理为梦圆。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500027463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688656"],"gpt_icon":0},{"id":"2580247298","title":"每周股票复盘：浩欧博（688656）股东户数增19.69%，Q3净利增113%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580247298","media":"证券之星","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580247298?lang=zh_cn&edition=full","pubTime":"2025-11-02 06:38","pubTimestamp":1762036693,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，浩欧博报收于164.35元，较上周的151.62元上涨8.4%。本周，浩欧博10月31日盘中最高价报165.58元。浩欧博当前最新总市值104.33亿元，在医疗器械板块市值排名37/126，在两市A股市值排名1820/5163。股本股东变化截至2025年9月30日，浩欧博股东户数为3727.0户，较6月30日增加613.0户，增幅19.69%。业绩披露要点浩欧博2025年三季报显示，前三季度主营收入2.92亿元，同比下降4.84%；归母净利润2618.92万元，同比下降1.41%；扣非净利润1672.3万元，同比下降33.93%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200001375.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688656"],"gpt_icon":0},{"id":"2579101891","title":"浩欧博（688656）2025年三季报简析：净利润同比下降1.41%，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2579101891","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579101891?lang=zh_cn&edition=full","pubTime":"2025-10-31 06:35","pubTimestamp":1761863739,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期浩欧博发布2025年三季报。截至本报告期末，公司营业总收入2.92亿元，同比下降4.84%，归母净利润2618.92万元，同比下降1.41%。本报告期浩欧博公司应收账款体量较大，当期应收账款占最新年报归母净利润比达137.88%。去年的净利率为9.15%，算上全部成本后，公司产品或服务的附加值一般。持有浩欧博最多的基金为农银医疗保健股票，目前规模为14.87亿元，最新净值1.6737，较上一交易日下跌1.7%，近一年上涨15.47%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100009134.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688656"],"gpt_icon":0},{"id":"2579080519","title":"图解浩欧博三季报：第三季度单季净利润同比增长113.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579080519","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579080519?lang=zh_cn&edition=full","pubTime":"2025-10-29 20:00","pubTimestamp":1761739236,"startTime":"0","endTime":"0","summary":"证券之星消息，浩欧博2025年三季报显示，前三季度公司主营收入2.92亿元，同比下降4.84%；归母净利润2618.92万元，同比下降1.41%；扣非净利润1672.3万元，同比下降33.93%；其中2025年第三季度，公司单季度主营收入1.03亿元，同比下降1.64%；单季度归母净利润1402.0万元，同比上升113.01%；单季度扣非净利润636.37万元，同比上升0.74%；负债率14.11%，投资收益11.31万元，财务费用110.37万元，毛利率59.17%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900040903.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688656"],"gpt_icon":0},{"id":"2578500716","title":"每周股票复盘：浩欧博（688656）与罗氏诊断签合作框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2578500716","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578500716?lang=zh_cn&edition=full","pubTime":"2025-10-26 04:50","pubTimestamp":1761425416,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，浩欧博报收于151.62元，较上周的155.31元下跌2.38%。本周，浩欧博10月22日盘中最高价报169.44元。本周关注点公司公告汇总：浩欧博与罗氏诊断签署化学发光自身抗体检测产品合作框架协议，合作范围限于中国大陆地区。协议履行可能受宏观经济、行业政策及市场环境等因素影响，存在不确定性。该事项无需董事会或股东大会审议，不构成关联交易或重大资产重组。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600001355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688656"],"gpt_icon":0},{"id":"2577871548","title":"浩欧博（688656）披露签订合作框架协议暨风险提示公告，10月21日股价下跌1.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577871548","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577871548?lang=zh_cn&edition=full","pubTime":"2025-10-21 22:33","pubTimestamp":1761057191,"startTime":"0","endTime":"0","summary":"截至2025年10月21日收盘，浩欧博报收于161.0元，较前一交易日下跌1.41%，最新总市值为102.2亿元。该股当日开盘163.46元，最高167.92元，最低158.66元，成交额达1.38亿元，换手率为1.36%。公司近日发布公告称，江苏浩欧博生物医药股份有限公司与罗氏诊断产品（上海）有限公司于2025年10月21日签署《合作框架协议》，双方将在化学发光自身抗体检测产品领域开展合作。罗氏诊断将向浩欧博采购相关产品，并在其商业化体系内进行推广，范围为中国大陆地区。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102100037151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688656","BK0239"],"gpt_icon":0},{"id":"2577582405","title":"浩欧博(688656.SH)与罗氏诊断就化学发光自身抗体检测产品领域开展合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2577582405","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577582405?lang=zh_cn&edition=full","pubTime":"2025-10-21 19:27","pubTimestamp":1761046044,"startTime":"0","endTime":"0","summary":"智通财经APP讯，浩欧博 发布公告，公司与罗氏诊断产品(上海)有限公司签署《合作框架协议》，双方就化学发光自身抗体检测产品领域开展合作。本次签订《合作框架协议》是落实公司长期发展战略的重要举措。公司与罗氏诊断合作有利于增强公司在本土市场的品牌认可度，有利于进一步拓展公司在诊断试剂领域的市场份额，对公司发展具有积极的意义。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1357732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"浩欧博(688656.SH)与罗氏诊断就化学发光自身抗体检测产品领域开展合作","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688656","BK0239"],"gpt_icon":0},{"id":"2574850125","title":"10月10日浩欧博跌6.17%，农银医疗保健股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2574850125","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574850125?lang=zh_cn&edition=full","pubTime":"2025-10-10 16:28","pubTimestamp":1760084881,"startTime":"0","endTime":"0","summary":"证券之星消息，10月10日浩欧博跌6.17%，收盘报144.87元，换手率1.74%，成交量1.1万手，成交额1.63亿元。重仓浩欧博的前十大公募基金请见下表：该股最近90天内共有2家机构给出评级，增持评级2家。根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共11家，其中持有数量最多的公募基金为农银汇理基金的农银医疗保健股票。该公募基金现任基金经理为梦圆。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101000024859.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688656"],"gpt_icon":0},{"id":"2569241705","title":"浩欧博(688656.SH)：MM09舌下喷雾剂III期临床试验完成首批受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2569241705","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569241705?lang=zh_cn&edition=full","pubTime":"2025-09-24 19:34","pubTimestamp":1758713667,"startTime":"0","endTime":"0","summary":"近日，公司收到全资子公司上海浩欧博生物医药有限责任公司通知，由上海浩欧博与Inmunotek公司联合申报的脱敏药MM09舌下喷雾剂III期临床试验成功完成首批受试者入组给药。此外，依托广东省药品监督管理局“港澳药械通”政策支持，猫毛、狗毛及屋尘螨/粉尘螨三款单品已顺利获得“粤港澳大湾区内地临床急需进口港澳药品批件”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1349027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","III","BK0239","688656"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1771258132599,"stockEarnings":[{"period":"1week","weight":0.0568},{"period":"1month","weight":-0.0577},{"period":"3month","weight":-0.191},{"period":"6month","weight":0.3074},{"period":"1year","weight":0.7028},{"period":"ytd","weight":-0.0402}],"compareEarnings":[{"period":"1week","weight":0.0041},{"period":"1month","weight":-0.0107},{"period":"3month","weight":0.0229},{"period":"6month","weight":0.1042},{"period":"1year","weight":0.2249},{"period":"ytd","weight":0.0285}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏浩欧博生物医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"3727人(较上一季度增加19.69%)","perCapita":"17032股","listingDate":"2021-01-13","address":"江苏省苏州市虎丘区中国(江苏)自由贸易试验区苏州片区苏州工业园区东堰里路9号","registeredCapital":"6347万元","survey":" 江苏浩欧博生物医药股份有限公司的主营业务是体外诊断试剂的研发、生产和销售。公司的主要产品是IgE检测、食物特异性IgG检测、自免产品。","listedPrice":35.26},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"浩欧博(688656)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供浩欧博(688656)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"浩欧博,688656,浩欧博股票,浩欧博股票老虎,浩欧博股票老虎国际,浩欧博行情,浩欧博股票行情,浩欧博股价,浩欧博股市,浩欧博股票价格,浩欧博股票交易,浩欧博股票购买,浩欧博股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"浩欧博(688656)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供浩欧博(688656)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}